Poster presented today in Boston shows direct anti-tumor activity in mesothelioma models, reduced tumor PD-L1 alongside decreased pCREB, and strong TT-4 monotherapy activity with added benefit in anti ...
TipRanks on MSN
AlphaTON, Cyncado recaps preclinical mesothelioma data
AlphaTON Capital (ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, issued a ...
Post-conference recap highlights direct anti-tumor effects in epithelial and non-epithelioid mesothelioma models, >90% tumor growth inhibition in vivo when TT-4 was combined with anti-PD-1, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback